Mitochondria-targeted nitroxide, Mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 4, 2013, Pages 1529-1540

  Starenki, Dmytro ^a   Park, Jong In ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; CASPASE 3; MITOCHONDRIA TARGETED CARBOXYPROXYL; NITROXIDE; PROTEIN RET; TRIPHENYLPHOSPHONIUM; UNCLASSIFIED DRUG; VANDETANIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE ARREST; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; ENZYME REGULATION; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; THYROID MEDULLARY CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIC N-OXIDES; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MICE; MICE, NUDE; MITOCHONDRIA; NITROGEN OXIDES; ORGANOPHOSPHORUS COMPOUNDS; PIPERIDINES; QUINAZOLINES; THYROID NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MUS; VASCONCELLEA CANDICANS;

EID: 84876220468     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3671     Document Type: Article

References (40)

1. Tuttle RM, Ball DW, Byrd D, et al. Medullary carcinoma. J Natl Compr Canc Netw. 2010; 8: 512-530.
2. Agrawal N, Jiao Y, Sausen M, et al. 2012 Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab. 2013; 98: E364-E369.
3. Boichard A, Croux L, Al Ghuzlan A, et al. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. J Clin Endocrinol Metab. 2012; 97: E2031-E2035.
4. Ciampi R, Mian C, Fugazzola L, et al. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid. 2013; 1: 1-8.
5. Ichihara M, Murakumo Y, Takahashi M. RET and neuroendocrine tumors. Cancer Lett. 2004; 204: 197-211.
6. Degrauwe N, Sosa JA, Roman S, Deshpande HA. Vandetanib for the treatment of metastatic medullary thyroid cancer. Clin Med Insights Oncol. 2012; 6: 243-252.
7. Nagilla M, Brown RL, Cohen EE. Cabozantinib for the treatment of advanced medullary thyroid cancer. Adv Ther. 2012; 29: 925-934.
8. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012; 30: 134-141.
9. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012; 21: 297-308.
10. Chiarugi P, Fiaschi T. Redox signalling in anchorage-dependent cell growth. Cell Signal. 2007; 19: 672-682.
11. Rao VA, Klein SR, Bonar SJ, et al. The antioxidant transcription factor Nrf2 negatively regulates autophagy and growth arrest induced by the anticancer redox agent mitoquinone. J Biol Chem. 2010; 285: 34447-34459.
12. Weinberg F, Hamanaka R, Wheaton WW, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A. 2010; 107: 8788-8793.
13. Don AS, Hogg PJ. Mitochondria as cancer drug targets. Trends Mol Med. 2004; 10: 372-378.
14. Millard M, Pathania D, Shabaik Y, Taheri L, Deng J, Neamati N. 2010 Preclinical evaluation of novel triphenylphosphonium salts with broad-spectrum activity. PloS one. 5: pii: e13131.
15. Murphy MP, Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol. 2007; 47: 629-656.
16. Smith RA, Adlam VJ, Blaikie FH, et al. Mitochondria-targeted antioxidants in the treatment of disease. Ann N Y Acad Sci. 2008; 1147: 105-111.
17. Modica-Napolitano JS, Aprille JR. Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells. Adv Drug Deliv Rev. 2001; 49: 63-70.
18. Cheng G, Zielonka J, Dranka BP, et al. Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death. Cancer Res. 2012; 72: 2634-2644.
19. Arthan D, Hong SK, Park JI. Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells. Cancer Lett. 2010; 297: 31-41.
20. Park JI, Strock CJ, Ball DW, Nelkin BD. The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/ STAT pathway. Mol Cell Biol. 2003; 23: 543-554.
21. Park JI, Strock CJ, Ball DW, Nelkin BD. Interleukin-1β can mediate growth arrest and differentiation via the leukemia inhibitory factor/ JAK/STAT pathway in medullary thyroid carcinoma cells. Cytokine. 2005; 29: 125-134.
22. Dhanasekaran A, Kotamraju S, Karunakaran C, et al. Mitochondria superoxide dismutase mimetic inhibits peroxide-induced oxidative damage and apoptosis: role of mitochondrial superoxide. Free Radic Biol Med. 2005; 39: 567-583.
23. Hong SK, Yoon S, Moelling C, Arthan D, Park JI. Noncatalytic function of ERK1/2 can promote Raf/MEK/ERK-mediated growth arrest signaling. J Biol Chem. 2009; 284: 33006-33018.
24. Cheng G, Lopez M, Zielonka J, et al. Mitochondria-targeted nitroxides exacerbate fluvastatin-mediated cytostatic and cytotoxic effects in breast cancer cells. Cancer Biol Ther. 2011; 12: 707-717.
25. de Groot JW, Plaza Menacho I, Schepers H, et al. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia type 2A and 2B associated RET mutations. Surgery. 2006; 139: 806-814.
26. Morisi R, Celano M, Tosi E, et al. 2007 Growth inhibition of medullary thyroid carcinoma cells by pyrazolo-pyrimidine derivates. J Endocrinol Invest. 30: RC31-RC34.
27. Plaza-Menacho I, Mologni L, Sala E, et al. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem. 2007; 282: 29230-29240.
28. Rosen A, Casciola-Rosen L. Macromolecular substrates for the ICElike proteases during apoptosis. J Cell Biochem. 1997; 64: 50-54.
29. Vitagliano D, De Falco V, Tamburrino A, et al. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocr Relat Cancer. 2011; 18: 1-11.
30. Cabrera JR, Bouzas-Rodriguez J, Tauszig-Delamasure S, Mehlen P. RET modulates cell adhesion via its cleavage by caspase in sympathetic neurons. JBiol Chem. 2011; 286: 14628-14638.
31. Kalyanaraman B, Darley-Usmar V, Davies KJ, et al. Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations. Free Radic Biol Med. 2012; 52: 1-6.
32. Halliwell B. Oxidative stress and cancer: have we moved forward? Biochem J. 2007; 401: 1-11.
33. Gustafson DL, Bradshaw-Pierce EL, Merz AL, Zirrolli JA. Tissue distribution and metabolism of the tyrosine kinase inhibitor ZD6474 (Zactima) in tumor-bearing nude mice following oral dosing. J Pharmacol Exp Ther. 2006; 318: 872-880.
34. Smith RA, Porteous CM, Gane AM, Murphy MP. Delivery of bio-active molecules to mitochondria in vivo. Proc Natl Acad Sci USA. 2003; 100: 5407-5412.
35. Chen Z, Lu W, Garcia-Prieto C, Huang P. The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr. 2007; 39: 267-274.
36. +)-ATPase in cultured cells. Biochim Biophys Acta. 1984; 804: 419-426.
37. Chen ZX, Velaithan R, Pervaiz S. mitoEnergetics and cancer cell fate. Biochim Biophys Acta. 2009; 1787: 462-467.
38. Kallinowski F, Schlenger KH, Kloes M, Stohrer M, Vaupel P. Tumor blood flow: the principal modulator of oxidative and glycolytic metabolism, and of the metabolic micromilieu of human tumor xenografts in vivo. Int J Cancer. 1989; 44: 266-272.
39. 2 or as SOD mimics? J Biol Chem. 1996; 271: 26026-26031.
40. Du J, Cullen JJ, Buettner GR. Ascorbic acid: chemistry, biology and the treatment of cancer. Biochim Biophys Acta. 2012; 1826: 443-457.